Phase 1/2a clinical trial of BI-1206, an anti-CD32b (FcγRIIB) antibody, in combination with pembrolizumab in subjects with advanced solid tumors previously treated with anti-PD-1/PD-L1.

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

Journal of Clinical Oncology

Topics

Medicine

Cancer Oncology

Immunology

Internal Medicine

Radiology, Nuclear Medicine And Imaging

Show all topics

DOI

10.1200/jco.2024.42.16_suppl.2593